NSE: STAR | BSE: 532531

Strong Performer, Under Radar

Download real time

1055.50 66.30 (6.70%)

37.32% Gain from 52W Low

560.8K NSE+BSE Volume

NSE 12 Jun, 2026 3:31 PM (IST)

9,728.8

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Search Inside the pdf :

Strides Pharma Science Ltd.

27 Mar 2026

1055.50

6.70%

STRIDES PHARMA SCIENCE LIMITED

Buy: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

The company reiterated its $400mn revenue target for FY28, supported by over 60 pending low-competition U.S. launches, while management remains constructive on other regulated markets, where an expanding product portfolio and new customer additions are expected to drive stronger growth and eventually scale these markets to revenue levels comparable with the U.S. business....

Strides Pharma Scien.. has an average target of 1119.00 from 1 broker.

Strides Pharma Science Ltd.

11 Nov 2025

1055.50

6.70%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Management remains optimistic about performance in other regulated markets, anticipating stronger revenue growth in FY26 as European partners prepare for product launches. The company also expects these markets to eventually generate...

Strides Pharma Science Ltd. is trading below its 30 day SMA of 1101.2

Strides Pharma Science Ltd.

24 Oct 2024

1055.50

6.70%

Continued momentum with another strong quarter

Buy: Strides Pharma Science Ltd.

Target

Sharekhan

Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.

Strides Pharma Science Ltd. is trading below its 30 day SMA of 1101.2

Strides Pharma Science Ltd.

27 Aug 2024

1055.50

6.70%

STRIDES PHARMA SCIENCE LIMITED

Sell: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Strides Pharma Science Ltd. is trading above its 200 day SMA of 926.8

Strides Pharma Science Ltd.

26 Dec 2023

1055.50

6.70%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Strides Pharma Science Ltd. is trading below its 30 day SMA of 1101.2

Strides Pharma Science Ltd.

31 Oct 2023

1055.50

6.70%

Mixed results, divestment to revitalize operating performance

Hold: Strides Pharma Science Ltd.

Recommendation

ICICI Securities Limited

Strides Pharma Science (Strides)’s Q2FY24 revenue growth (up 11% YoY) was better, though EBITDA margins (adj. margins at 16.8%) were a tad weaker than anticipated. Revenue growth in the quarter was driven by other regulated markets (35% YoY) and Africa (up 36%). Strides is re-grouping its CDMO business under one umbrella ‘Onesource’ – this entity will likely clock revenues of USD 400mn in FY27, from USD 150mn in FY24E.

Strides Pharma Scien.. has an average target of 1119.00 from 1 broker.

Strides Pharma Science Ltd.

26 Sep 2023

1055.50

6.70%

Regrouping CDMO pieces to unlock value

Sell: Strides Pharma Science Ltd.

Recommendation Target

ICICI Securities Limited

Strides Pharma (Strides) is streamlining its CDMO business by merging its soft gel capsule business and injectable business of Steriscience with Stelis. It will also rename Stelis to OneSource after completion, and regrouping will help the promoter better align the focus on all the arms of the CDMO business. The combined entity is likely to have revenue of USD 180-200mn in FY25E and management expects to grow 20-25% p.a. thereon.

Promoters unpledged 3.33% of shares in last quarter. Total pledge stands at 27.27% of promoter holdings

Strides Pharma Science Ltd.

03 Aug 2023

1055.50

6.70%

Striving to improve margin; valuations pricey

Hold: Strides Pharma Science Ltd.

Recommendation Target

ICICI Securities Limited

Strides Pharma Science’s (Strides) Q1FY24 earnings exhibited a healthy beat on margin front. Improved product mix, cost-optimisation initiatives and freight costs led to expansions in gross margin (+880bps YoY) and EBITDA margin (+1,250bps). Management aspires to improve from these levels going ahead. Adjusted for divested businesses, revenue recorded a healthy 11% YoY growth.